Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced its financial results for the quarter ended September 30, 2010.

1 Nov 2010

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Life Technologies announces launch of new sequencer to deliver genomic data

Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.

1 Nov 2010

Biodel receives FDA CRL for Linjeta NDA

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) requesting additional information regarding the company's new drug application (NDA) for Linjeta™ (human insulin [rDNA origin]) injection 100IU/mL for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.

1 Nov 2010

Dyadem opens second office to meet customer demand for enterprise risk management software

Dyadem today announced the opening of its second office in Europe; located in Starnberg, Germany, on the outskirts of Munich. Dyadem, the leader in Operational and Quality Risk Management, has expanded in response to a surge in customer demand in the European Union for its enterprise risk management software and services amid heightened scrutiny of safety and quality standards for companies in the oil & gas, chemical, medical device and pharmaceutical industries.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Experts at ICB-2010 Conference to discuss new research findings in biotherapy

The 8th International Conference on Biotherapy (ICB-2010) will be held in Los Angeles, November 11-14, 2010, at the Universal Los Angeles Hilton. It is the single most important meeting for sharing new clinical and research findings in biotherapy (living organisms used to treat or diagnose illness).

30 Oct 2010

Progress update on Johnson & Johnson and Crucell's public offer

Pursuant to the provisions of Section 7 paragraph 1(a) of the Dutch Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement within four weeks following the announcement of an intended public offer to provide a status update, Johnson & Johnson (NYSE: JNJ) and Crucell N.V. provide the following joint update.

30 Oct 2010

Hikma to acquire Baxter's US generic injectables business

Hikma Pharmaceuticals PLC ("Hikma"), the fast growing multinational pharmaceutical group, announces that it has signed an agreement to acquire Baxter Healthcare Corporation's US generic injectables business ("Multi-Source Injectables" or the "Business") for a cash consideration of $112 million.

30 Oct 2010

Agilent opens new life sciences instruments manufacturing facility in Singapore

Agilent Technologies Inc. today announced the opening of its new life sciences instruments manufacturing facility in Singapore. The facility will produce the company's Liquid Chromatography/Mass Spectrometry (LC/MS) instruments for the global market.

30 Oct 2010

Caraco third quarter net sales increases from $78.4 million to $97.8 million

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $97.8 million and $227.8 million during the second quarter ended September 30, 2010 and first six months of the Company's current fiscal year ended September 30, 2010, respectively, as compared to $78.4 million and $126.4 million, respectively, for the corresponding periods of the previous fiscal year ended September 30, 2009.

30 Oct 2010

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Noble metals such as platinum and palladium are becoming increasingly important because of growth in environmentally friendly applications such as fuel cells and pollution control catalysts. But the world has limited quantities of these materials, meaning manufacturers will have to rely on efficient recycling processes to help meet the demand.

29 Oct 2010

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

From Baxter International Inc. 29 Oct 2010

Boston Scientific's Neurovascular business to be acquired by Stryker

Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months.

From Stryker 29 Oct 2010

Manufacturing News and Research

Further Reading

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Life Technologies announces launch of new sequencer to deliver genomic data

Biodel receives FDA CRL for Linjeta NDA

Dyadem opens second office to meet customer demand for enterprise risk management software

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Experts at ICB-2010 Conference to discuss new research findings in biotherapy

Progress update on Johnson & Johnson and Crucell's public offer

Hikma to acquire Baxter's US generic injectables business

Agilent opens new life sciences instruments manufacturing facility in Singapore

Caraco third quarter net sales increases from $78.4 million to $97.8 million

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Baxter to divest U.S. generic injectables business to Hikma

Boston Scientific's Neurovascular business to be acquired by Stryker

Talecris third quarter net revenue increases 2.8% to $407.0 million

Stryker enters agreement to acquire assets of Neurovascular division of Boston Scientific

IntriCon third quarter net sales increases 14% to $14.7 million

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News